Semaglutide was added in 2024, and markers of tirzepatide were added from 1 January 2026, both monitored in and out of competition
Upper endoscopy results show a troubling pattern of leftover food in GLP-1RA users' stomachs, even after proper fasting
There has also been revealing on a study on ferroptosis in HSCs
The primary competitive variable is not pricing but clinical differentiation through head-to-head efficacy comparisons and outcomes trial results
In addition to distal expression within the progenitor zone (PZ), SYGL-1 and LST-1 are present in the proximal gonad, consistent with their mRNA expression [18, 19]
The STEP clinical trial programme, published in the New England Journal of Medicine, demonstrated average weight reductions of approximately 15% of body weight over 68 weeks in adults without type 2 diabetes